
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …

Sweden-based Biopharma firm Symphogen has appointed Annika Espander Jansson as a non-executive director to its board. Jansson has over 20 …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

